Passive Immunity Should and Will Work for COVID-19 for Some Patients

Area of Science:

• Immunology
• Virology
• Pharmacology

Background:

• Passive immunotherapy is crucial for severe acute respiratory syndrome-CoV-2 (SARS-CoV-2) due to limited antiviral options and evolving vaccines.
• Approaches include donor plasma, intravenous immunoglobulins, and monoclonal antibodies targeting viral components like the Spike protein.

Purpose of the Study:

• To explore the complexities and potential of passive immunotherapy for SARS-CoV-2 treatment and prevention.
• To highlight the importance of understanding dose, timing, bioavailability, and antibody effector functions.

Main Methods:

• Review of laboratory and clinical data on passive immunotherapy for SARS-CoV-2.
• Analysis of viral targets, including the Spike protein's receptor binding domain and N-terminal domain.
• Consideration of polyclonal antibody approaches for broader efficacy.

Main Results:

• Passive immunotherapy demonstrates potential for beneficial protective and treatment outcomes.
• Dose and time dependencies are critical factors influencing efficacy.
• Antibody effector functions, beyond neutralization, may play a significant role.

Conclusions:

• A strong polyclonal antibody approach may offer advantages against viral diversity and mutations.
• Product availability, administration ease, and patient variability are crucial considerations for clinical success.
• Tailoring passive immunotherapy to individual patient variability and viral nuances is essential for improving outcomes.